BACKGROUND: This meta-analysis of randomized controlled trials aimed to systematically evaluate the value of albuterol in the treatment of patients with acute respiratory distress syndrome(ARDS).DATA SOURCES: Randomiz...BACKGROUND: This meta-analysis of randomized controlled trials aimed to systematically evaluate the value of albuterol in the treatment of patients with acute respiratory distress syndrome(ARDS).DATA SOURCES: Randomized controlled trials on albuterol treatment of ARDS from its inception to October 2014 were searched systematically. The databases searched included: Pub Med, Ovid EMBASE, Ovid Cochrane, CNKI, WANFANG and VIP. The trials were screened according to the pre-designed inclusion and exclusion criteria. We performed a systematic review and meta-analysis of the randomized controlled trials(RCTs) on albuterol treatment, attempting to improve outcomes, i.e. lowering the 28-day mortality and ventilator-free days.RESULTS: Three RCTs involving 646 patients met the inclusion criteria. There was no significant decrease in the 28-day mortality(risk difference=0.09; P=0.07, P for heterogeneity=0.22, I2=33%). The ventilator-free days and organ failure-free days were significantly lower in the patients who received albuterol(mean difference=–2.20; P<0.001, P for heterogeneity=0.49, I2=0% and mean difference=–1.71, P<0.001, P for heterogeneity=0.60, I2=0%).CONCLUSIONS: Current evidences indicate that treatment with albuterol in the early course of ARDS was not effective in increasing the survival, but significantly decreasing the ventilator-free days and organ failure-free days. Owing to the limited number of included trails, strong recommendations cannot be made.展开更多
studies have shown that the R- and S-enantiomers of racemic albuterol, a β2-adrenergic receptor agonist used in asthma treatment, have differential effects on the contractile properties of airway smooth muscle. Howev...studies have shown that the R- and S-enantiomers of racemic albuterol, a β2-adrenergic receptor agonist used in asthma treatment, have differential effects on the contractile properties of airway smooth muscle. However, the effect of albuterol on the proliferation and migration has never been tested. Since (R)-, but not (S)-albuterol enhances bronchodilation, we expect the two racemic isomers would also affect proliferation and migration of tracheal cells differentially. By monitoring migratory properties of airway smooth muscle cells in the presence of albuterol isomers, the different effect of albuterol on proliferation and migration of airway smooth muscle cells is probed. The results show Both of R- and S-albuterol could inhibit the proliferation of smooth muscle cells and the inhibition ratio of these two isomers had no significant difference;R-albuterol, but not S-albuterol, inhibited cell migration.展开更多
A library consisting of a series of O,O'-diaryzoyl-L-(-)-tartaric acids (2) was designed and synthesized. The substituent on the aromatic ring of 2 significantly affects the diastereomeric excess and efficiency of...A library consisting of a series of O,O'-diaryzoyl-L-(-)-tartaric acids (2) was designed and synthesized. The substituent on the aromatic ring of 2 significantly affects the diastereomeric excess and efficiency of the resolution of racemic albuterol (1). Excel-lent resolving reagent 2a was selected for the resolution of rac-1 via the parallel approach. However,a family of three resolving reagents failed to improve the resolution efficiency of rac-1.展开更多
基金supported by Guangxi Emergency Medicine and Rescue Fund(GXJZ201403)
文摘BACKGROUND: This meta-analysis of randomized controlled trials aimed to systematically evaluate the value of albuterol in the treatment of patients with acute respiratory distress syndrome(ARDS).DATA SOURCES: Randomized controlled trials on albuterol treatment of ARDS from its inception to October 2014 were searched systematically. The databases searched included: Pub Med, Ovid EMBASE, Ovid Cochrane, CNKI, WANFANG and VIP. The trials were screened according to the pre-designed inclusion and exclusion criteria. We performed a systematic review and meta-analysis of the randomized controlled trials(RCTs) on albuterol treatment, attempting to improve outcomes, i.e. lowering the 28-day mortality and ventilator-free days.RESULTS: Three RCTs involving 646 patients met the inclusion criteria. There was no significant decrease in the 28-day mortality(risk difference=0.09; P=0.07, P for heterogeneity=0.22, I2=33%). The ventilator-free days and organ failure-free days were significantly lower in the patients who received albuterol(mean difference=–2.20; P<0.001, P for heterogeneity=0.49, I2=0% and mean difference=–1.71, P<0.001, P for heterogeneity=0.60, I2=0%).CONCLUSIONS: Current evidences indicate that treatment with albuterol in the early course of ARDS was not effective in increasing the survival, but significantly decreasing the ventilator-free days and organ failure-free days. Owing to the limited number of included trails, strong recommendations cannot be made.
文摘studies have shown that the R- and S-enantiomers of racemic albuterol, a β2-adrenergic receptor agonist used in asthma treatment, have differential effects on the contractile properties of airway smooth muscle. However, the effect of albuterol on the proliferation and migration has never been tested. Since (R)-, but not (S)-albuterol enhances bronchodilation, we expect the two racemic isomers would also affect proliferation and migration of tracheal cells differentially. By monitoring migratory properties of airway smooth muscle cells in the presence of albuterol isomers, the different effect of albuterol on proliferation and migration of airway smooth muscle cells is probed. The results show Both of R- and S-albuterol could inhibit the proliferation of smooth muscle cells and the inhibition ratio of these two isomers had no significant difference;R-albuterol, but not S-albuterol, inhibited cell migration.
基金supported by the National Natural Science Foundation of China (29790125,29972039 and 20025205)
文摘A library consisting of a series of O,O'-diaryzoyl-L-(-)-tartaric acids (2) was designed and synthesized. The substituent on the aromatic ring of 2 significantly affects the diastereomeric excess and efficiency of the resolution of racemic albuterol (1). Excel-lent resolving reagent 2a was selected for the resolution of rac-1 via the parallel approach. However,a family of three resolving reagents failed to improve the resolution efficiency of rac-1.
